Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 12/20 | 0.49 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSB | P07858 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2035892 | 1.00 | MAOB (0.52) | MAOBCTSSCTSKCTSBCTSL | |
| SCHEMBL2473923 | 0.84 | ATM (0.43) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL6316889 | 0.84 | ATM (0.43) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL27489128 | 0.84 | ATM (0.43) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL8907586 | 0.84 | L3MBTL1 (0.43) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL6316448 | 0.83 | ATM (0.42) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL13995754 | 0.82 | REN (0.46) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL24093689 | 0.81 | ATM (0.41) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2014842 | 0.81 | ATM (0.41) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3807212 | 0.81 | ATM (0.41) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
| WO-2010086366-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | MAOB 444/4885CTSS 3940/4885CTSK 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.